Data to be presented in oral and ePoster presentations St Andrews, UK “ 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for...
Study achieves primary & secondary endpoints in a randomised, placebo-controlled challenge studyNeumifil delivers a statistically significant reduction in both symptomatic infection rate &...
Neumifil is being developed for the prevention and treatment of virus induced exacerbations in patients with respiratory diseaseAdvancing Neumifil into a Phase 2b clinical study due to start in 2024 ...
Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent
ST ANDREWS, Scotland, Sept. 28, 2022 /PRNewswire/ -- Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today announced the appointment of five world leading experts in respiratory and infectious diseases to its newly formed Clinical Advisory Group (CAG). The CAG will work closely with the Pneumagen management team to support its clinical development programmes, with an emphasis on the continued rapid and successful progress of its lead drug candidate, Neumifil.
Pneumagen, a clinical stage biotech company developing Neumifil, an intranasal, broad-spectrum antiviral treatment to prevent or, if infected reduce...
ST ANDREWS, Scotland, May 12, 2022 /PRNewswire/ -- Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today reports positive topline data from a Phase 1 study with Neumifil designed to evaluate safety and tolerability in healthy volunteers.
ST ANDREWS, Scotland, May 10, 2022 /PRNewswire/ -- Pneumagen, a clinical stage biotech company developing Neumifil, a novel intranasal spray which is designed to provide patients at risk with an easy to use, pan-anti-viral treatment to reduce, prevent and manage respiratory disease exacerbations caused by viral infections, announces the appointment of Dr. John Beadle, Founder and former Chief Executive Officer of PsiOxus Therapeutics Ltd, as a Non-Executive director of the company.
ST ANDREWS, Scotland, Jan. 19, 2022 /PRNewswire/ -- Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today announced it has raised a further £3.8m to advance clinical development and manufacturing of its lead product Neumifil.
St. Andrews, Scotland – Pneumagen Ltd, a biotech company developing a universal pan-viral intranasal drug for protection against respiratory tract infections (RTIs), today announced a further milestone in the development of Neumifil™ for the treatment of COVID-19. Utilizing a hamster model of COVID-19 infection, researchers showed Neumifil was efficacious, significantly reducing clinical signs and weight loss in animals infected with SARS-CoV-2.